lamivudine + abacavir + amprenavir + nelfinavir

This drug is a combination of four antiretroviral agents: **lamivudine** and **abacavir**, which are nucleoside reverse transcriptase inhibitors (NRTIs), plus **amprenavir** and **nelfinavir**, which are protease inhibitors (PIs). These drugs act in complementary ways to inhibit HIV replication by blocking two key enzymes required for viral replication: reverse transcriptase and protease. Lamivudine and abacavir inhibit viral reverse transcriptase activity, leading to chain termination during DNA synthesis, while amprenavir and nelfinavir prevent protease-mediated cleavage of viral polyproteins, thereby producing immature, non-infectious viral particles. This high-potency multi-drug regimen may be used in HIV-1 infection, typically as a customized prescription for patients who require non-standard therapy or have demonstrated resistance to other first-line regimens[1].